ALTのチャート
ALTの企業情報
| symbol | ALT |
|---|---|
| 会社名 | Altair Engineering Inc （アルテアエンジニアリング） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ IT・通信（IT_Communications） |
| 概要 | 事業概要 Altimmune Inc. formerly Pharmathene Inc. is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies RespirVec and Densigen. Its candidates include NasoVAX HepTcell NasoShield and Oncosyn. NasoVAX is an intranasally administered recombinant influenza vaccine. The Company has completed Phase I clinical trials of NasoVAX. HepTcell is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus. NasoShield is an intranasal single-dose anthrax vaccine designed to provide rapid stable protection after one intranasal administration. Oncosyn is being developed as a cancer immunotherapeutic product candidate. Oncosyn targets multiple tumor antigens simultaneous to prevent tumor escape. アルテアエンジニアリングは米国のソフトウェア企業。製品設計開発に関わるソフトウェアの開発、販売、サ―ビスをグロ―バルに展開する。同社製品にはHyperWorks、solidThinking、PBS Works、Runtime、Carriotsがあり、CAE、工業デザイン、IoT、クラウドコンピュ―ティングなどに最適な環境を提供する。本社はミシガン州トロイ。 altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current |
| 本社所在地 | 1820 East Big Beaver Road Troy MI 48083 USA |
| 代表者氏名 | Mitchel B. Sayare ミッチェル・B.・セイヤー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 240-654-1450 |
| 設立年月日 | 1985年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 2400人 |
| url | www.altair.com |
| nasdaq_url | https://www.nasdaq.com/symbol/alt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -18.35489 |
| 終値（lastsale） | 4.93 |
| 時価総額（marketcap） | 8482148.81 |
| 時価総額 | 時価総額（百万ドル） 19.07799 |
| 売上高 | 売上高（百万ドル） 12.50890 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 16.72822 |
| 当期純利益 | 当期純利益（百万ドル） -57.28126 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Altimmune Inc revenues increased 53% to $5.1M. Net loss applicable to common stockholders increased 90% to $14.9M. Revenues reflect License revenue remaining flat at $10K. Higher net loss reflects Research and Development - Balancing val increase of 33% to $10.5M (expense) General and administrativ increase of 51% to $5M (expense) Stock-based Compensation in R&D increase of 26% to $197K (expense). |
ALTのテクニカル分析
ALTのニュース
Altimmune, Inc. (ALT) Q1 2023 Earnings Call Transcript 2023/05/11 19:56:08 Seeking Alpha
Altimmune, Inc. (NASDAQ:NASDAQ:ALT) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ETCompany ParticipantsRich Eisenstadt - Chief Financial OfficerVipin Garg - Chief Executive…
Earnings Scheduled For May 11, 2023 2023/05/11 13:58:54 Benzinga
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE: TAK ) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ: XELA ) is expected to report earnings for its first quarter. • Addex Therapeutics (NASDAQ: ADXN ) is projected to report earnings for its first quarter. • Fiverr Intl (NYSE: FVRR ) is expected to report quarterly earnings at $0.24 per share on revenue of $87.66 million. • Teekay (NYSE: TK ) is likely to report earnings for its first quarter. • Teekay Tankers (NYSE: TNK ) is likely to report quarterly earnings at $4.38 per share on revenue of $243.55 million. • Pharming (NASDAQ: PHAR ) is likely to report earnings for its first quarter. • Algonquin Power (NYSE: AQN ) is expected to report quarterly earnings at $0.23 per share on revenue of $983.76 million. • Docebo (NASDAQ: DCBO ) is projected to report quarterly earnings at $0.02 per share on revenue of $55.42 million. • Pioneer Muni High Inc (NYSE: MAV ) is estimated to report quarterly loss at $0.
Altimmune: Q1 Earnings Insights 2023/05/11 11:06:00 Benzinga
Altimmune (NASDAQ: ALT ) reported its Q1 earnings results on Thursday, May 11, 2023 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Altimmune beat estimated earnings by 16.67%, reporting an EPS of $-0.4 versus an … Full story available on Benzinga.com
Altimmune GAAP EPS of -$0.40 beats by $0.08 2023/05/11 11:01:28 Seeking Alpha
Altimmune press release (ALT): Q1 GAAP EPS of -$0.40 beats by $0.08.Cash, cash equivalents and short-term investments totaled $165.8 million as of March 31, 2023.
Altimmune, Inc: Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update 2023/05/11 11:01:00 Finanz Nachrichten
Initiation of the IMPACT Phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (NASH) expected mid-2023 Top-line 48-week results from the MOMENTUM Phase 2 obesity trial expected Q4 2023 To…
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy 2023/04/28 10:26:31 InvestorPlace
The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022. The gains in biotech were in stark contrast to the broader market. All the major exchanges were down last year with growth investors finding few places to hide. But growth-oriented investors don’t have to look back too far to see how quickly things can change. In 2021, biotech stocks were down 25% and even the most innovative biotech stocks found it hard to get a bid. There are many reasons why things are different. There’s a more promising regulatory environment for starters. But many of these companies are also achieving success in clinical trials that make real innovation seem possible. This article will look at three biotech companies that are offering promising innovations that could provide catalysts for their respective stocks in 2023. As I like to do, I’m offering you one large cap, one mid-cap, and one small-cap stock for your consideration. Let’s get to the list! BIIB Biogen $293.72 AXSM Axsome Therapeutics $71.16 ALT Altimmune $4.96 Biogen (BIIB) Source: aslysun / Shutterstock.com The large cap on this list of biotech stocks is Biogen (NASDAQ: BIIB ).
7 Biotech Stocks With Huge Return Potential for Long-Term Investors 2023/04/27 00:01:50 InvestorPlace
Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can’t just introduce health-related products directly to the market. Instead, they must undergo intensive clinical tests to ensure broader public safety. During these processes, plenty of things can go wrong, thus introducing volatility to the space. Still, investors who want to maximize the return potential of their speculation-earmarked funds should consider the best biotech stocks for 2023. Specifically, this list will target decently stable enterprises with massive upside targets, as determined by Wall Street analysts. And by massive, I really mean that. The majority of these biotech stocks with breakthrough products feature price targets that imply triple-digit percentage gains. And one, in particular, enjoys a 733% upside forecast. Of course, the other side to this equation is that you must be willing to accept serious risks. If that’s you, these are the biotech stocks with high growth potential.
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell, an Immunotherapeutic for Chronic Hepatitis B 2023/04/11 11:30:00 Wallstreet:Online
GAITHERSBURG, Md., April 11, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the Company), today announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (CHB). With the achievement of this milestone, data readout is planned for the first quarter of 2024.
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B 2023/04/11 11:30:00 GlobeNewswire
GAITHERSBURG, Md., April 11, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the Company), today announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (CHB). With the achievement of this milestone, data readout is planned for the first quarter of 2024.
7 Cheap Stocks That Are Worth Your Attention 2023/04/03 10:15:35 InvestorPlace
There’s a natural attraction to having cheap stocks. Nobody wants to overpay for an equity in their portfolio. And if you have $10,000 to invest it’s a lot easier – and more satisfying – to buy a lot of shares of a company than just a handful priced at $500 or so. But cheap stocks don’t mean bottom-of-the-barrel picks. You can find some amazing values with the right cheap stocks if you know how to identify the ones that have the best potential to outperform the market in the coming months. That’s where the Portfolio Grader comes in. My free tool gives an “A” through “F” rating to every stock, based on earnings history, stock performance, sentiment, buying momentum and other factors. Investors can look for cheap stocks with a good “A” or “B” grade and have some assurance that there’s muscle behind those low, low prices. But here’s a word of warning – some of these stocks have a pretty low market capitalization and are classified as penny stocks . That means they don’t have the resources as big large-cap names have to buy their way out of trouble.
Small Cap Stock Altimmune Inc. (ALT) Is A Buy – Analysts 2023/01/03 14:30:00 Marketing Sentinel
Altimmune Inc. (NASDAQ:ALT) has a beta value of 0.17 and has seen 1.75 million shares traded in the last trading session. The company, currently valued at $789.44M, closed the last trade at $16.45 per share which meant it gained $0.39 on the day or 2.43% during that session. The ALT stock price is -42.8% off … Small Cap Stock Altimmune Inc. (ALT) Is A Buy – Analysts Read More »
Altimmune Touts Encouraging Data From Fatty Liver Disease Study 2022/12/20 17:42:15 Benzinga
Altimmune Inc (NASDAQ: ALT ) announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with Non-Alcoholic Fatty Liver Disease (NAFLD). Sixty-six of the 83 subjects who completed the initial 12-week Phase 1b NAFLD trial consented to participate in this 12-week extension trial to receive 24 weeks of treatment, and 64 subjects were enrolled. The trial met its primary … Full story available on Benzinga.com
Goldman Sachs reiterates ''buy'' on Altimmune following positive data 2022/12/20 16:03:05 Investing.com
https://www.investing.com/news/pro/goldman-sachs-reiterates-buy-on-altimmune-following-positive-data-432SI-2968004
Altimmune rises 5% on positive data from phase 1 trial of Non-Alcoholic Fatty Liver Disease treatment 2022/12/20 13:59:15 Seeking Alpha
Altimmune (ALT) is trading ~5% higher premarket after a second part of an early stage trial of its drug, pemvidutide, to treat Non-Alcoholic Fatty Liver Disease (NAFLD)…
Do you want to know where to find good stock? Take a look at Altimmune Inc.’s (NASDAQ:ALT) Sentiment Analysis 2022/12/19 20:08:00 US Post News
Currently, Altimmune Inc.’s (ALT) stock is trading at $9.55, marking a fall of -16.81% from last night’s close. At this price, the stock is -59.34% below its 52-week high of $23.49 and 149.35% above its 52-week low of $3.83. Based on the past 30-day period, the stock price is -14.21% below the high and +21.59% […]